Skip to main content

Table 1 Baseline demographics of the cohort

From: Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry

  Total Cohort TPV/PR BOC/PR
  n = 309 n = 215 n = 94
Age – Years, Median (IQR) 46 (38–54) 45 (38–54) 47 (39–56)
BMI – kg/m2 Median (IQR) 26.5 (23.5–28.8) 26.3 (23.9–28.5) 25.9 (21.4–30.6)
Male, n (%) 212/290 (73.1%) 149/202 (73.8%) 63/88 (71.6%)
History of cirrhosis, n (%) 79/291 (27.1%) 55/198 (27.8%) 24/93 (25.8%)
Treatment Experienced, n (%) 89/306 (29.1%) 66/212 (31.1%) 23/94 (24.5%)
HIV co-infected, n (%) 23/313 (7.3%) 23/198 (11.6%)
IL28B Allele, n (%)
 CC 92/269 (34.2%) 59/179 (33%) 31/86 (36%)
 CT 144/269 (53.5%) 96/179 (53.6%) 47/86 (54.5%)
 TT 33/269 (12.3%) 24/179 (13.4%) 8/86 (9.3%)
Genotype, n (%)
 G1a 172/309 (55.7%) 119/215 (55.3%) 53/94 (56.4%)
 G1b 86/309 (27.8%) 55/215 (25.6%) 31/94 (33%)
 G1 – unspecified 51/309 (16.5%) 41/215 (19.1%) 10/94 (10.6%)
Acquisition Risk Factor
 IVDU 133/309 (43%) 89/215 (41.7%) 44/94 (46.8%)
 Anti-D 28/309 (9.1%) 18/215 (8.4%) 10/94 (10.6%)
 Blood product 36/309 (11.7%) 31/215 (14.4%) 5/94 (5.3%)
 Other 15/309 (4.9%) 11/215 (5.1%) 4/94 (4.4%)
 Unknown/not reported 97/309 (31.4%) 66/215 (30.7%) 31/94 (32.9%)
Baseline HCV-RNA >800,000 IU/ml 153/286 (53.5%) 98/196 (50%) 55/90 (61.1%)
  1. Missing data is a common problem with observational data. Percentages are calculated based on the proportion of available data